Entinostat for treatment of solid tumors and hematologic malignancies.
about
Trials with 'epigenetic' drugs: an updateComparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families.ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells.Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signalingThe class I histone deacetylase inhibitor MS-275 prevents pancreatic beta cell death induced by palmitate.Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aEntinostat up-regulates the CAMP gene encoding LL-37 via activation of STAT3 and HIF-1α transcription factors.Rapid screening of novel agents for combination therapy in sarcomasMicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer.Targeting class I histone deacetylases in cancer therapy.Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.Entinostat: a promising treatment option for patients with advanced breast cancer.HDACs and HDAC Inhibitors in Cancer Development and Therapy.Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer.Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.The effect of MS-275 on CYP450 isoforms activity in rats by cocktail method.E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.Novel therapeutics in glaucoma management.Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
P2860
Q27000542-C97D41E1-37D8-472D-B09E-8C3BA7EC0212Q30886620-ECE9C775-34B8-4BC3-8FFD-00A6D79EA659Q33432027-B7AF707E-C508-484D-BC5A-A244E537A346Q34496371-B2DE3C55-7BBF-4E98-AB2F-3A9D3B6D909DQ34559028-95C43501-D177-4BC5-8FBD-EE8B0E1585D9Q34956310-21BB78D5-E7FA-4765-A28F-B2059E184347Q36938662-02F7E46E-F8AE-4BB0-8AC8-607F1C68E9D6Q37260765-A4B6842B-1878-4102-AA5E-84F0A25C8710Q37298877-2025D9AC-B96A-4A41-A776-6DA175A1856BQ37437269-0642983A-2A4C-4132-ADF4-719A783E2C3EQ38051736-9E0BF10B-EFD8-42FA-9D35-BC40575A5C83Q38534163-32E96551-848F-46B9-BDA8-553DA12303DDQ38741783-1C6E609E-DC63-4A91-B825-C18552E1DA4FQ38947405-10BDF334-32C9-4B60-9EA5-2C2720EF3145Q39047967-349F7A09-810B-4D3D-A1FC-74157DD3910CQ39062353-71000D77-F9B0-433D-9B89-905F5B060833Q39177415-7D2A5FF1-9134-4BE2-8EFB-1C868175FD4BQ39185574-F2833E6E-9060-4E25-888C-B25130E0AF64Q41883101-2F890268-E6A7-499C-9A6C-31A8937B68DDQ48200103-0BB42A93-832E-49CF-AB4E-C41A45E8E3E4Q50023818-E9758065-7445-42AF-A4DD-5050512FD0CDQ58130496-79B52A40-05D7-4945-8432-2320949D0A2D
P2860
Entinostat for treatment of solid tumors and hematologic malignancies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Entinostat for treatment of solid tumors and hematologic malignancies.
@en
Entinostat for treatment of solid tumors and hematologic malignancies.
@nl
type
label
Entinostat for treatment of solid tumors and hematologic malignancies.
@en
Entinostat for treatment of solid tumors and hematologic malignancies.
@nl
prefLabel
Entinostat for treatment of solid tumors and hematologic malignancies.
@en
Entinostat for treatment of solid tumors and hematologic malignancies.
@nl
P2860
P1476
Entinostat for treatment of solid tumors and hematologic malignancies.
@en
P2093
Jeffrey Knipstein
P2860
P304
P356
10.1517/13543784.2011.613822
P407
P577
2011-09-02T00:00:00Z